FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gert Ossenkoppele

Research Profile

Disorders

Procedures

Anatomy

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
M Terwijn; A A Van De Loosdrecht; Sonja Zweegman; A N Snel; Angèle Kelder; Gert Ossenkoppele; Y J M Oussoren; A P Rutten; W J Scholten; Gerrit J Schuurhuis
Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
J J W M Janssen; Angèle Kelder; Jan J Cornelissen; W Deenik; Walter Pouwels; Gerrit J Schuurhuis; K G M Smolders; B J van Kuijk; Gert Ossenkoppele
Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
Marvin M van Luijn; Theresia M Westers; Martine E D Chamuleau; Gert Ossenkoppele; S Marieke Van Ham; Arjan A van de Loosdrecht
Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gert Ossenkoppele (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: M Terwijn; A A Van De Loosdrecht; Sonja Zweegman; A N Snel; Angèle Kelder; Gert Ossenkoppele; Y J M Oussoren; A P Rutten; W J Scholten; Gerrit J Schuurhuis
Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
International journal of laboratory hematology 2012;34(4):432-41.
2012: J J W M Janssen; Angèle Kelder; Jan J Cornelissen; W Deenik; Walter Pouwels; Gerrit J Schuurhuis; K G M Smolders; B J van Kuijk; Gert Ossenkoppele
Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
Leukemia 2012;26(5):977-84.
2011: Marvin M van Luijn; Theresia M Westers; Martine E D Chamuleau; Gert Ossenkoppele; S Marieke Van Ham; Arjan A van de Loosdrecht
Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.
The American journal of pathology 2011;179(5):2157-61.
2011: Shikhar Aggarwal; Arjan A van de Loosdrecht; Canan Alhan; Gert Ossenkoppele; Theresia M Westers; Hetty J Bontkes
Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
British journal of haematology 2011;153(5):568-81.
2011: M E D Chamuleau; S M G Jirka; Gert Ossenkoppele; Gerrit J Schuurhuis; L van Dreunen; Anna van Rhenen; Adri Zevenbergen; Arjan A van de Loosdrecht
High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Leukemia research 2011;35(6):741-9.
2011: Gert Ossenkoppele; Arjan A van de Loosdrecht; Gerrit Jan Schuurhuis
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
British journal of haematology 2011;153(4):421-36.
2011: David C de Leeuw; Willemijn van den Ancker; Theresia M Westers; Anne H Loonen; Shama L Bhola; Gert Ossenkoppele; Arjan A van de Loosdrecht
Challenging diagnosis in a patient with clear lymphoid immunohistochemical features and myeloid morphology: mixed phenotype acute leukemia with erythrophagocytosis.
Leukemia research 2011;35(5):693-6.
2011: Theresia M Westers; Willemijn van den Ancker; Hetty J Bontkes; Jeroen J W M Janssen; Arjan A van de Loosdrecht; Gert Ossenkoppele
Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.
Immunotherapy 2011;3(4):569-76.
2011: Roel J W van Kampen; Carme Canals; Harry C Schouten; Arnon Nagler; Kirsty J Thomson; Jean-Paul Vernant; Agnes Buzyn; Marc A Boogaerts; Jian-Jian Luan; Sébastien Maury; Noel J Milpied; Jean-Pierre Jouet; Gert Ossenkoppele; Anna Sureda
Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(10):1342-8.
2011: Marvin M van Luijn; Willemijn van den Ancker; Martine E D Chamuleau; Adri Zevenbergen; Theresia M Westers; Gert Ossenkoppele; S Marieke Van Ham; Arjan A van de Loosdrecht
Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
Cancer research 2011;71(7):2507-17.
2011: Bob Löwenberg; Thomas Pabst; Edo Vellenga; Wim L J van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Bart J Biemond; Alois Gratwohl; Georgine E De Greef; Leo F Verdonck; M Ronald Schaafsma; Michael Gregor; Matthias Theobald; Urs Schanz; Johan Maertens; Gert Ossenkoppele
Cytarabine dose for acute myeloid leukemia.
The New England journal of medicine 2011;364(11):1027-36.
2011: Karin P M van Galen; Sonja Zweegman; Gert Ossenkoppele
Pancreatic pseudocyst in an adult patient after treatment with pegylated asparaginase.
British journal of haematology 2011;152(6):676.
2011: Willemijn van den Ancker; Marvin M van Luijn; Jurjen M Ruben; Theresia M Westers; Hetty J Bontkes; Gert Ossenkoppele; Tanja D de Gruijl; Arjan A van de Loosdrecht
Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
Cancer immunology, immunotherapy : CII 2011;60(1):37-47.
2010: Wendy Deenik; Bronno van der Holt; Jeroen J W M Janssen; Isabel W T Chu; Peter J M Valk; Gert Ossenkoppele; Ilse P van der Heiden; Pieter Sonneveld; Ron van Schaik; Jan J Cornelissen
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.
Blood 2010;116(26):6144-5; author reply 6145-6.
2010: Josien C Regelink; Cinthy H M van Roessel; Karin P M van Galen; Gert Ossenkoppele; Peter C Huijgens; Sonja Zweegman
Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(35):e741-3; author reply e744-5.
2010: Marvin M van Luijn; Martine E D Chamuleau; Maaike E Ressing; Emmanuel J Wiertz; Suzanne Ostrand-Rosenberg; Yuri Souwer; Adri Zevenbergen; Gert Ossenkoppele; Arjan A van de Loosdrecht; S Marieke Van Ham
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.
Cancer immunology, immunotherapy : CII 2010;59(12):1825-38.
2010: Bob Löwenberg; Gareth Morgan; Gert Ossenkoppele; Alan K Burnett; Pierre Zachée; Ulrich Dührsen; Daan Dierickx; Carsten Müller-Tidow; Pieter Sonneveld; Utz Krug; Elisabeth Bone; Nicolas Flores; Alison F Richardson; Leon Hooftman; Chris Jenkins; Sonja Zweegman; Faith Davies
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(28):4333-8.
2010: Pau Montesinos; José D González; José González; Chelo Rayón; Elena de Lisa; Maria L Amigo; Gert Ossenkoppele; María J Peñarrubia; Manuel Pérez-Encinas; Juan Bergua; Guillermo Deben; María J Sayas; Javier de la Serna; Josep M Ribera; Javier Bueno; Gustavo Milone; Concepción Rivas; Salut Brunet; Bob Löwenberg; Miguel Sanz
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3872-9.
2010: J J W M Janssen; Fedor Denkers; Peter J M Valk; Jan J Cornelissen; Gerrit J Schuurhuis; Gert Ossenkoppele
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells.
Haematologica 2010;95(6):1036-7.
2010: Wendy Deenik; J J W M Janssen; Bronno van der Holt; Gregor Verhoef; Willem M Smit; Marie José Kersten; Simon M G J Daenen; Leo F Verdonck; Augustin Ferrant; A V M B Schattenberg; Pieter Sonneveld; Marinus van Marwijk Kooy; Shulamiet Wittebol; Roelof Willemze; Pierre W Wijermans; Berna Beverloo; Bob Löwenberg; Peter J M Valk; Gert Ossenkoppele; Jan J Cornelissen
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.
Haematologica 2010;95(6):914-21.
2010: Bob Löwenberg; Joachim Beck; Carlos Graux; Wim van Putten; Harry C Schouten; Leo F Verdonck; Augustin Ferrant; Pieter Sonneveld; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Dimitri Breems; Hilde de Muijnck; Ron Schaafsma; Gregor Verhoef; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gert Ossenkoppele; Johan Maertens
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
Blood 2010;115(13):2586-91.
2010: Saskia A G M Cillessen; Chris J L M Meijer; Michitaka Notoya; Gert Ossenkoppele; Joost Oudejans
Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
The Journal of pathology 2010;220(5):509-20.
2010: Theresia M Westers; Canan Alhan; Martine E D Chamuleau; Maurice J D L van der Vorst; Corien Eeltink; Gert Ossenkoppele; Arjan A van de Loosdrecht
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.
Blood 2010;115(9):1779-84.
2010: Marvin M van Luijn; Martine E D Chamuleau; James A Thompson; Suzanne Ostrand-Rosenberg; Theresia M Westers; Yuri Souwer; Gert Ossenkoppele; S Marieke Van Ham; Arjan A van de Loosdrecht
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
Haematologica 2010;95(3):485-93.
2010: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo Coco; Tomoki Naoe; Dietger Niederwieser; Gert Ossenkoppele; MA Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Blood 2010;115(3):453-74.
2010: Marvin M van Luijn; W van den Ancker; Martine E D Chamuleau; Gert Ossenkoppele; S Marieke Van Ham; Arjan A van de Loosdrecht
Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.
Immunotherapy 2010;2(1):85-97.
2010: Willemijn van den Ancker; Marvin M van Luijn; Theresia M Westers; Hetty J Bontkes; Jurjen M Ruben; Tanja D de Gruijl; Gert Ossenkoppele; Arjan A van de Loosdrecht
Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.
Immunotherapy 2010;2(1):69-83.
2009: Aafke Meerveld-Eggink; Ankie M T van der Velden; Gert Ossenkoppele; Arjan A van de Loosdrecht; Douwe H Biesma; Ger T Rijkers
Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(12):1523-30.
2009: Jeroen J W M Janssen; Henk W Berendse; Gerrit-Jan Schuurhuis; Pauline A Merle; Gert Ossenkoppele
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
American journal of hematology 2009;84(10):679-82.
2009: Bob Löwenberg; Gert Ossenkoppele; Wim L J van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
High-dose daunorubicin in older patients with acute myeloid leukemia.
The New England journal of medicine 2009;361(13):1235-48.
2009: Jean-Luc Harousseau; Giovanni Martinelli; Wieslaw W Jedrzejczak; Joseph M Brandwein; Dominique Bordessoule; Tamas Masszi; Gert Ossenkoppele; Julia A Alexeeva; Gernot Beutel; Johan Maertens; Maria-Belen Vidriales; Hervé Dombret; Xavier Thomas; Alan K Burnett; Tadeusz Robak; Nuriet K Khuageva; Anatoly K Golenkov; Elena Tothova; Lars Mollgard; Youn C Park; Annick Bessems; Peter De Porre; Angela J Howes
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood 2009;114(6):1166-73.
2009: Willemijn van den Ancker; Monique Terwijn; Josien Regelink; Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht; Sonja Zweegman
Uncommon lineage switch warrants immunophenotyping even in relapsing leukemia.
Leukemia research 2009;33(7):e77-80.
2009: Yuri Souwer; Martine E D Chamuleau; Arjan A van de Loosdrecht; Eva Tolosa; Tineke Jorritsma; Jettie J F Muris; Marion J Dinnissen-van Poppel; Sander N Snel; Lisette van de Corput; Gert Ossenkoppele; Chris J L M Meijer; Jacques J Neefjes; S Marieke van Ham
Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
British journal of haematology 2009;145(3):334-43.
2009: M E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert Ossenkoppele; Arjan A van de Loosdrecht
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.
Haematologica 2009;94(4):496-506.
2009: Jan J Cornelissen; Bronno van der Holt; Gregor Verhoef; Mars B van't Veer; Marinus H J van Oers; Harry C Schouten; Gert Ossenkoppele; Pieter Sonneveld; Johan Maertens; Marinus van Marwijk Kooy; M Ronald Schaafsma; Pierre W Wijermans; Douwe H Biesma; Shulamiet Wittebol; Paul J Voogt; Joke W Baars; Pierre Zachée; Leo F Verdonck; Bob Löwenberg; Adriaan W Dekker
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
Blood 2009;113(6):1375-82.
2009: Canan Alhan; Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht
Do peripheral blasts count in myelodysplastic syndromes?
Leukemia research 2009;33(2):209-11.
2009: Corine J Hess; Nicole Feller; Fedor Denkers; Angèle Kelder; Pauline A Merle; Michael C Heinrich; Amy Harlow; Johannes Berkhof; Gert Ossenkoppele; Quinten Waisfisz; Gerrit J Schuurhuis
Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.
Haematologica 2009;94(1):46-53.
2009: A A van de Loosdrecht; W van den Ancker; Ilse Houtenbos; Gert Ossenkoppele; Theresia M Westers
Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
Handbook of experimental pharmacology 2009;(188):319-48.
2008: M E D Chamuleau; Arjan A van de Loosdrecht; Corine J Hess; J J W M Janssen; Adri Zevenbergen; Ruud Delwel; Peter J M Valk; Bob Löwenberg; Gert Ossenkoppele
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.
Haematologica 2008;93(12):1894-8.
2008: Willemijn van den Ancker; Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht
Back to basics: in search of the optimal dendritic cell for vaccination in AML.
Leukemia research 2008;32(11):1641-3.
2008: Corine J Hess; a Errami; Johannes Berkhof; Fedor Denkers; Gert Ossenkoppele; Anders O H Nygren; Gerrit J Schuurhuis; Quinten Waisfisz
Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia.
Leukemia & lymphoma 2008;49(6):1132-41.
2008: Ilse Houtenbos; Saskia Santegoets; Theresia M Westers; Quinten Waisfisz; Sergey Kipriyanov; Fedor Denkers; Rik J Scheper; Tanja D de Gruijl; Gert Ossenkoppele; Arjan A van de Loosdrecht
The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.
British journal of haematology 2008;142(2):273-83.
2008: Joost van Galen; Jettie J F Muris; Cindy P E Giroth; Wim Vos; Gert Ossenkoppele; C J L M Meijer; Joost Oudejans
Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
Histopathology 2008;52(5):578-84.
2008: Wendy Deenik; Bronno van der Holt; Gregor Verhoef; Willem M Smit; Marie J Kersten; Hanneke C Kluin-Nelemans; Leo F Verdonck; Augustin Ferrant; A V M B Schattenberg; Jeroen J W M Janssen; Pieter Sonneveld; Marinus van Marwijk Kooy; Shulamiet Wittebol; Roelof Willemze; Pierre W Wijermans; Petra H M Westveer; Berna Beverloo; Peter Valk; Bob Löwenberg; Gert Ossenkoppele; Jan J Cornelissen
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Blood 2008;111(5):2581-8.
2008: Marielle J Wondergem; Servi J C Stevens; Jeroen J W M Janssen; Joost Oudejans; Gert Ossenkoppele; Jaap Middeldorp; Sonja Zweegman
Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression.
Blood 2008;111(3):1739; author reply 1739-40.
2008: Arjan A van de Loosdrecht; Theresia M Westers; August H Westra; Angelika M Dräger; Vincent H J van der Velden; Gert Ossenkoppele
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
Blood 2008;111(3):1067-77.
2008: Arjan A van de Loosdrecht; Theresia M Westers; Gert Ossenkoppele
Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication?
Leukemia research 2008;32(2):205-7.
2008: Corine J Hess; Najim Ameziane; Gerrit J Schuurhuis; a Errami; Fedor Denkers; G J L Kaspers; Jacqueline Cloos; Hans Joenje; Dirk Reinhardt; Gert Ossenkoppele; Christian M Zwaan; Quinten Waisfisz
Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2008;30(4):299-306.
2008: Nicole Feller; Angèle Kelder; Guus Westra; Gert Ossenkoppele; Gerrit J Schuurhuis
Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.
Cytometry. Part B, Clinical cytometry 2008;74(1):9-16.
2008: Bijan Moshaver; Marjolein A van der Pol; August H Westra; Gert Ossenkoppele; Sonja Zweegman; Gerrit J Schuurhuis
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival.
Leukemia & lymphoma 2008;49(1):134-48.
2008: Saskia A G M Cillessen; John C Reed; Kate Welsh; Clemencia Pinilla; Richard A Houghten; Erik Hooijberg; José Deurhof; Kitty C M Castricum; Pim Kortman; Corine J Hess; Gert Ossenkoppele; Chris J L M Meijer; Joost Oudejans
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells.
Blood 2008;111(1):369-75.
2007: Saskia A G M Cillessen; Corine J Hess; Erik Hooijberg; Kitty C M Castricum; Pim Kortman; Fedor Denkers; Wim Vos; Mark A van de Wiel; Gerrit J Schuurhuis; Gert Ossenkoppele; Chris J L M Meijer; Joost Oudejans
Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(23):7012-21.
2007: Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil N Bhalla; Giuliana Alimena; Francesca Palandri; Gert Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark R Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood 2007;110(10):3540-6.
2007: Anna van Rhenen; Guus A M S van Dongen; Angèle Kelder; Elwin J Rombouts; Nicole Feller; Bijan Moshaver; Marijke Stigter-van Walsum; Sonja Zweegman; Gert Ossenkoppele; Gerrit Jan Schuurhuis
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
Blood 2007;110(7):2659-66.
2007: Anna van Rhenen; Bijan Moshaver; Angèle Kelder; Nicole Feller; A W M Nieuwint; Sonja Zweegman; Gert Ossenkoppele; Gerrit J Schuurhuis
Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
Leukemia 2007;21(8):1700-7.
2007: Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht
Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2007;61(6):306-14.
2007: Anna van Rhenen; Bijan Moshaver; Gert Ossenkoppele; Gerrit Jan Schuurhuis
New approaches for the detection of minimal residual disease in acute myeloid leukemia.
Current hematologic malignancy reports 2007;2(2):111-8.
2007: Marry M van den Heuvel-Eibrink; Bronno van der Holt; Alan K Burnett; Wolfgang Knauf; Martin F Fey; Gregor Verhoef; Edo Vellenga; Gert Ossenkoppele; Bob Löwenberg; Pieter Sonneveld
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
Annals of hematology 2007;86(5):329-37.
2007: Corine J Hess; Johannes Berkhof; Fedor Denkers; Gert Ossenkoppele; Jan P Schouten; Joost Oudejans; Quinten Waisfisz; Gerrit J Schuurhuis
Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(10):1209-15.
2007: Leo F Verdonck; Annelise Notenboom; Daphne D de Jong; Marius A Mackenzie; Gregor Verhoef; Mark H H Kramer; Gert Ossenkoppele; Jeanette K Doorduijn; Pieter Sonneveld; Gustaaf W van Imhoff
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
Blood 2007;109(7):2759-66.
2007: Abdulbaqi Al-toma; Otto J Visser; Hyacintha M van Roessel; B Mary E von Blomberg; Wieke H M Verbeek; Petra E T Scholten; Gert Ossenkoppele; Peter C Huijgens; Chris J J Mulder
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells.
Blood 2007;109(5):2243-9.
2007: W Deenik; Bronno van der Holt; Gregor Verhoef; A V M B Schattenberg; Leo F Verdonck; S M G J Daenen; Pierre Zachée; Petra H M Westveer; W M Smit; Shulamiet Wittebol; Harry C Schouten; Bob Löwenberg; Gert Ossenkoppele; Jan J Cornelissen
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.
Annals of hematology 2007;86(2):117-25.
2007: Joost van Galen; Jettie J F Muris; Joost Oudejans; Wim Vos; Cindy P E Giroth; Gert Ossenkoppele; Arie P Otte; Frank M Raaphorst; Chris J L M Meijer
Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL.
Journal of clinical pathology 2007;60(2):167-72.
2007: Ilse Houtenbos; Theresia M Westers; Annemiek Dijkhuis; Tanja D de Gruijl; Gert Ossenkoppele; Arjan A van de Loosdrecht
Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):307-15.
2007: Jettie J F Muris; Bauke Ylstra; Saskia A G M Cillessen; Gert Ossenkoppele; Johanna C Kluin-Nelemans; Paul P Eijk; B Nota; Marloes R Tijssen; Wim P H de Boer; Mark A van de Wiel; Paul van den IJssel; P Jansen; PC de Bruin; J H J M van Krieken; Gerrit A Meijer; C J L M Meijer; Joost Oudejans
Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas.
British journal of haematology 2007;136(1):38-47.
2006: Anita Keijzer; Paul Van Der Valk; Gert Ossenkoppele; Arjan A van de Loosdrecht
Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha.
Haematologica 2006;91(12 Suppl):ECR51.
2006: Ilse Houtenbos; Theresia M Westers; Corine J Hess; Quinten Waisfisz; Gert Ossenkoppele; Arjan A van de Loosdrecht
Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells.
Leukemia 2006;20(10):1892-5.
2006: Jettie J F Muris; Chris J L M Meijer; Gert Ossenkoppele; Wim Vos; Joost Oudejans
Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma.
Hematological oncology 2006;24(3):97-104.
2006: Saskia A G M Cillessen; Chris J L M Meijer; Gert Ossenkoppele; Kitty C M Castricum; August H Westra; Petra Niesten; Jettie J F Muris; Hoite F Nijdam; Klaas G van der Hem; Marcel Flens; Erik Hooijberg; Joost Oudejans
Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.
British journal of haematology 2006;134(3):283-93.
2006: Ilse Houtenbos; Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht
Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia.
British journal of haematology 2006;134(4):445-6; author reply 446-7.
2006: Jettie J F Muris; C J L M Meijer; Wim Vos; J H J M van Krieken; N Mehdi Jiwa; Gert Ossenkoppele; Joost Oudejans
Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
The Journal of pathology 2006;208(5):714-23.
2006: Ilse Houtenbos; Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht
Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.
Haematologica 2006;91(3):348-55.
2006: Ilse Houtenbos; Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht
Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
Immunobiology 2006;211(6-8):677-85.
2006: Theresia M Westers; Ilse Houtenbos; Arjan A van de Loosdrecht; Gert Ossenkoppele
Principles of dendritic cell-based immunotherapy in myeloid leukemia.
Immunobiology 2006;211(6-8):663-76.
2006: M E D Chamuleau; Gert Ossenkoppele; Arjan A van de Loosdrecht
MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation.
Immunobiology 2006;211(6-8):619-25.
2006: Theresia M Westers; J J W M Janssen; Ilse Houtenbos; N C L Snoijs; Arjan A van de Loosdrecht; Gert Ossenkoppele
Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens.
Leukemia 2006;20(1):154-7.
2005: Bronno van der Holt; Bob Löwenberg; Alan K Burnett; Wolfgang Knauf; John Shepherd; Pier Paolo Piccaluga; Gert Ossenkoppele; Gregor Verhoef; Augustin Ferrant; Michael Crump; Dominik Selleslag; Matthias Theobald; Martin F Fey; Edo Vellenga; Margaret Dugan; Pieter Sonneveld
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
Blood 2005;106(8):2646-54.
2005: Hanneke M van der Straaten; Anja van Biezen; Ronald Brand; A V M B Schattenberg; Roel M Egeler; Renée M Y Barge; Jan J Cornelissen; Harry C Schouten; Gert Ossenkoppele; Leo F Verdonck
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
Haematologica 2005;90(10):1339-45.
2005: Anna van Rhenen; Nicole Feller; Angèle Kelder; August H Westra; Elwin Rombouts; Sonja Zweegman; Marjolein A van der Pol; Quinten Waisfisz; Gert Ossenkoppele; Gerrit J Schuurhuis
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6520-7.
2005: Nicole Feller; Marjolein A van der Pol; Taco Waaijman; G W D Weijers; Guus Westra; Gert Ossenkoppele; Gerrit J Schuurhuis
Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4793-801.
2005: Theresia M Westers; Ilse Houtenbos; Gerrit J Schuurhuis; Gert Ossenkoppele; Arjan A van de Loosdrecht
Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2005;66(1):71-7.
2005: Theresia M Westers; Ilse Houtenbos; N C L Snoijs; Arjan A van de Loosdrecht; Gert Ossenkoppele
Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity.
Leukemia 2005;19(7):1270-2.
2005: Alexander D Cornet; Aart I Issa; Arjan A van de Loosdrecht; Gert Ossenkoppele; R J M Strack van Schijndel; A B Johan Groeneveld
Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care.
European journal of haematology 2005;74(6):511-6.
2005: J J W M Janssen; S M Klaver; Quinten Waisfisz; G Pasterkamp; Dominique P V de Kleijn; Gerrit J Schuurhuis; Gert Ossenkoppele
Identification of genes potentially involved in disease transformation of CML.
Leukemia 2005;19(6):998-1004.
2005: Gustaaf W van Imhoff; Bronno van der Holt; Marius A Mackenzie; Mars B van't Veer; Pierre W Wijermans; Gert Ossenkoppele; Harry C Schouten; Pieter Sonneveld; Monique M C Steijaert; Philip M Kluin; Hanneke C Kluin-Nelemans; Leo F Verdonck
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3793-801.
2005: Gustaaf W van Imhoff; Bronno van der Holt; Marius A Mackenzie; Gert Ossenkoppele; Pierre W Wijermans; Mark H H Kramer; Mars B van 't Veer; Harry C Schouten; Marinus van Marwijk Kooy; Marinus H J van Oers; John M M Raemaekers; Pieter Sonneveld; L A M H Meulendijks; Philip M Kluin; Hanneke C Kluin-Nelemans; Leo F Verdonck
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Leukemia 2005;19(6):945-52.
2005: Amber van Stijn; Nicole Feller; Astrid Kok; Marjolein A van der Pol; Gert Ossenkoppele; Gerrit J Schuurhuis
Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(7):2540-6.
2005: Jettie J F Muris; Saskia A G M Cillessen; Wim Vos; Inge Saskia van Houdt; J Alain Kummer; J H J M van Krieken; N Mehdi Jiwa; Patty M Jansen; Hanneke C Kluin-Nelemans; Gert Ossenkoppele; Chad Gundy; Chris J L M Meijer; Joost Oudejans
Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.
Blood 2005;105(7):2916-23.
2005: Dimitri A Breems; Wim L J van Putten; Peter C Huijgens; Gert Ossenkoppele; Gregor Verhoef; Leo F Verdonck; Edo Vellenga; Georgine E De Greef; Emanuel Jacky; Johannes Van Der Lelie; Marc Boogaerts; Bob Löwenberg
Prognostic index for adult patients with acute myeloid leukemia in first relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1969-78.
2005: Carin A Uyl-de Groot; Ivonne Buijt; I J M Gloudemans; Gert Ossenkoppele; H P Berg; Peter C Huijgens
Health related quality of life in patients with multiple myeloma undergoing a double transplantation.
European journal of haematology 2005;74(2):136-43.
2005: Theresia M Westers; Ilse Houtenbos; Arjan A van de Loosdrecht; Gert Ossenkoppele
Divergent autologous T cell responses to leukaemic dendritic cells during remission in acute promyelocytic leukaemia.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2005;27(4):261-6.
2005: Ilse Houtenbos; Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht
Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
Immunobiology 2005;210(2-4):249-57.
2005: Nicole Feller; Martine C Jansen-van der Weide; Marjolein A van der Pol; Guus Westra; Gert Ossenkoppele; Gerrit J Schuurhuis
Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
Experimental hematology 2005;33(1):120-30.
2004: Corine J Hess; Fedor Denkers; Gert Ossenkoppele; Quinten Waisfisz; Cathal J McElgunn; Eric Eldering; Jan P Schouten; Gerrit J Schuurhuis
Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method.
Leukemia 2004;18(12):1981-8.
2004: Alexander B H Bakker; Sonja van den Oudenrijn; Arjen Q Bakker; Nicole Feller; Marja Van Meijer; Judith A Bia; Mandy A C Jongeneelen; Therese J Visser; Nora Bijl; Cecilia A W Geuijen; Wilfred Marissen; Katarina Radosevic; Mark Throsby; Gerrit J Schuurhuis; Gert Ossenkoppele; John de Kruif; Jaap Goudsmit; Ada M Kruisbeek
C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.
Cancer research 2004;64(22):8443-50.
2004: Arjan A van de Loosdrecht; Peter C Huijgens; Gert Ossenkoppele
Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma.
Current opinion in hematology 2004;11(6):419-25.
2004: M E D Chamuleau; Yuri Souwer; S Marieke Van Ham; Adri Zevenbergen; Theresia M Westers; Johannes Berkhof; Chris J L M Meijer; Arjan A van de Loosdrecht; Gert Ossenkoppele
Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.
Cancer research 2004;64(16):5546-50.
2004: Nicole Feller; Marjolein A van der Pol; Amber van Stijn; G W D Weijers; August H Westra; B W Evertse; Gert Ossenkoppele; Gerrit J Schuurhuis
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia.
Leukemia 2004;18(8):1380-90.
2004: Ilse Houtenbos; Theresia M Westers; Tanja D de Gruijl; Rik J Scheper; Gert Ossenkoppele; Arjan A van de Loosdrecht
TNF-alpha receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells.
Leukemia 2004;18(6):1149-53.
2004: J J W M Janssen; A Hochhaus; Johan W van Oostveen; Quinten Waisfisz; Gerrit J Schuurhuis; Gert Ossenkoppele
Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
Leukemia 2004;18(5):1020-1.
2004: Gert Ossenkoppele; Wilfried J Graveland; Pieter Sonneveld; S M G J Daenen; Douwe H Biesma; Leo F Verdonck; M Ronald Schaafsma; Petra H M Westveer; Godefridus J Peters; Paul Noordhuis; Petra Muus; Dominik Selleslag; Bronno van der Holt; Michel Delforge; Bob Löwenberg; Gregor Verhoef
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Blood 2004;103(8):2908-13.
2004: Amber van Stijn; Astrid Kok; M A van Stalborch; Marjolein A van der Pol; Nicole Feller; August H Westra; Gert Ossenkoppele; Gerrit J Schuurhuis
Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile.
Leukemia 2004;18(4):875-7.
2004: Arjan A van de Loosdrecht; Peter C Huijgens; Gert Ossenkoppele
Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications.
Anti-cancer drugs 2004;15(3):189-201.
2004: Jettie J F Muris; C J L M Meijer; Saskia A G M Cillessen; Wim Vos; J Alain Kummer; Bellinda A Bladergroen; M J J T Bogman; M A MacKenzie; N Mehdi Jiwa; L H Siegenbeek van Heukelom; Gert Ossenkoppele; Joost Oudejans
Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.
Leukemia 2004;18(3):589-96.
2003: Rosita L ten Berge; PC de Bruin; Joost Oudejans; Gert Ossenkoppele; Paul Van Der Valk; C J L M Meijer
ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
Histopathology 2003;43(5):462-9.
2003: Anita G M Stam; Saskia J A M Santegoets; Theresia M Westers; Claudia C Sombroek; J J W M Janssen; Bryan W Tillman; Arjan A van de Loosdrecht; HERBERT PINEDO; David T Curiel; Gert Ossenkoppele; Rik J Scheper; Tanja D de Gruijl
CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation.
British journal of cancer 2003;89(7):1162-5.
2003: Marjolein A van der Pol; Nicole Feller; Marjet Roseboom; Bijan Moshaver; Guus Westra; Henk J Broxterman; Gert Ossenkoppele; Gerrit J Schuurhuis
Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells.
Haematologica 2003;88(9):983-93.
2003: Marjolein A van der Pol; Henk J Broxterman; Guus Westra; Gert Ossenkoppele; Gerrit J Schuurhuis
Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples.
Cytometry. Part B, Clinical cytometry 2003;55(1):14-21.
2003: Jeanette K Doorduijn; Bronno van der Holt; Gustaaf W van Imhoff; Klaas G van der Hem; Mark H H Kramer; Marinus H J van Oers; Gert Ossenkoppele; M Ronald Schaafsma; Leo F Verdonck; Gregor Verhoef; Monique M C Steijaert; Ivonne Buijt; Carin A Uyl-de Groot; Michel van Agthoven; Andries H Mulder; Pieter Sonneveld
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3041-50.
2003: Ilse Houtenbos; Theresia M Westers; Gert Ossenkoppele; Arjan A van de Loosdrecht
Identification of CD14 as a predictor for leukemic dendritic cell differentiation in acute myeloid leukemia.
Leukemia 2003;17(8):1683-4; author reply 1684; discussion 1685.
2003: Marjolein A van der Pol; Nicole Feller; Gert Ossenkoppele; G W D Weijers; August H Westra; Amber van Stijn; Henk J Broxterman; Gerrit J Schuurhuis
Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis.
Leukemia 2003;17(8):1674-7.
2003: Gert Ossenkoppele; Anita G M Stam; Theresia M Westers; Tanja D de Gruijl; J J W M Janssen; Arjan A van de Loosdrecht; Rik J Scheper
Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells.
Leukemia 2003;17(7):1424-6.
2003: Ilse Houtenbos; Theresia M Westers; Anita G M Stam; Tanja D de Gruijl; Rik J Scheper; Gert Ossenkoppele; Arjan A van de Loosdrecht
Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation.
Cancer immunology, immunotherapy : CII 2003;52(7):455-62.
2003: Amber van Stijn; Marjolein A van der Pol; Astrid Kok; Petra M Bontje; Guido M J M Roemen; Robert H J Beelen; Gert Ossenkoppele; Gerrit J Schuurhuis
Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia.
Haematologica 2003;88(5):497-508.
2003: Rosita L ten Berge; Joost Oudejans; Gert Ossenkoppele; Chris J L M Meijer
ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.
The Journal of pathology 2003;200(1):4-15.
2003: Amber van Stijn; Astrid Kok; Marjolein A van der Pol; Nicole Feller; Guido M J M Roemen; August H Westra; Gert Ossenkoppele; Gerrit J Schuurhuis
Multiparameter flow cytometric quantification of apoptosis-related protein expression.
Leukemia 2003;17(4):787-8.
2003: Amber van Stijn; Astrid Kok; Marjolein A van der Pol; Nicole Feller; Guido M J M Roemen; August H Westra; Gert Ossenkoppele; Gerrit J Schuurhuis
A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia.
Leukemia 2003;17(4):780-6.
2003: Marjolein A van der Pol; Henk J Broxterman; Jennie M Pater; Nicole Feller; Martin van der Maas; G W D Weijers; George L Scheffer; John D Allen; Rik J Scheper; Arnold van Loevezijn; Gert Ossenkoppele; Gerrit J Schuurhuis
Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
Haematologica 2003;88(2):134-47.
2003: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Wim L J van Putten; Peter J M Valk; Sonja van der Poel-van de Luytgaarde; Ronald Hack; Rosalyn Slater; Elisabeth M E Smit; Berna Beverloo; Gregor Verhoef; Leo F Verdonck; Gert Ossenkoppele; Pieter Sonneveld; Georgine E De Greef; Bob Löwenberg; Ruud Delwel
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Blood 2003;101(3):837-45.
2003: Theresia M Westers; Anita G M Stam; Rik J Scheper; Johanna C Regelink; A W M Nieuwint; Gerrit J Schuurhuis; Arjan A van de Loosdrecht; Gert Ossenkoppele
Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia.
Cancer immunology, immunotherapy : CII 2003;52(1):17-27.
2003: Nicole Feller; Gerrit J Schuurhuis; Marjolein A van der Pol; Guus Westra; G W D Weijers; Amber van Stijn; Peter C Huijgens; Gert Ossenkoppele
High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome.
Leukemia 2003;17(1):68-75.
2002: David R Colnot; Gert Ossenkoppele; Jan C Roos; Jasper J Quak; Remco de Bree; Pontus K E Börjesson; Peter C Huijgens; Gordon B Snow; Guus A M S van Dongen
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3401-6.
2002: Ilse Houtenbos; Gert Ossenkoppele
Acute myeloid leukemia in a 23-year-old patient with Beckwith-Wiedemann syndrome.
Cancer genetics and cytogenetics 2002;136(1):90-1.
2002: Andries R Jonkhoff; Arne M de Kreuk; Gaby Franschman; Johannes Van Der Lelie; Gerrit J Schuurhuis; Angelika M Dräger; Sonja Zweegman; Peter C Huijgens; Gert Ossenkoppele
Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma.
British journal of haematology 2002;118(1):90-100.
2002: Danny F Dukers; Chris J L M Meijer; Rosita L ten Berge; Wim Vos; Gert Ossenkoppele; Joost Oudejans
High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome.
Blood 2002;100(1):36-42.
2002: Rosita L ten Berge; Chris J L M Meijer; Danny F Dukers; J Alain Kummer; Bellinda A Bladergroen; Wim Vos; C Erik Hack; Gert Ossenkoppele; Joost Oudejans
Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma.
Blood 2002;99(12):4540-6.
2002: NL Ramakers-van Woerden; Rob Pieters; D Hoelzer; Rosalyn M Slater; Monique L den Boer; Anne H Loonen; Jochen Harbott; Gritta E Janka-Schaub; W-D Ludwig; Gert Ossenkoppele; Elisabeth R van Wering; Anjo J P Veerman
In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Medical and pediatric oncology 2002;38(6):379-86.
2002: Sonja Zweegman; Maarten H Vermeer; Marcel W Bekkink; Paul Van Der Valk; Prabath Nanayakkara; Gert Ossenkoppele
Leukaemia cutis: clinical features and treatment strategies.
Haematologica 2002;87(4):ECR13.
2002: Fransien de Boer; Angelika M Dräger; HERBERT PINEDO; Floortje L Kessler; ELSKEN VAN DER WALL; Andries R Jonkhoff; Johannes Van Der Lelie; Peter C Huijgens; Gert Ossenkoppele; Gerrit J Schuurhuis
Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation.
Bone marrow transplantation 2002;29(3):249-55.
2002: J A E Somers; S O A Shamelian; Bob Löwenberg; Gert Ossenkoppele; Jan J Cornelissen
[STI571: a new dimension in the treatment of chronic myeloid leukemia].
Nederlands tijdschrift voor geneeskunde 2002;146(3):128-32.
2001: Marjolein A van der Pol; Jennie M Pater; Nicole Feller; August H Westra; Amber van Stijn; Gert Ossenkoppele; Henk J Broxterman; Gerrit J Schuurhuis
Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia.
Leukemia 2001;15(10):1554-63.
2001: Arne M de Kreuk; Andries R Jonkhoff; Adri Zevenbergen; E C Hendriks; Gerrit J Schuurhuis; Gert Ossenkoppele; Angelika M Dräger; Johan W van Oostveen; Peter C Huijgens
Storage of unprocessed G-CSF-mobilized whole blood in a modified Leibovitz's L15 medium preserves clonogenic capacity for at least 7 days.
Bone marrow transplantation 2001;28(2):145-55.
2001: Peter C Huijgens; H M Dekker-Van Roessel; Andries R Jonkhoff; G C Admiraal; Sonja Zweegman; Gerrit J Schuurhuis; Gert Ossenkoppele
High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
Bone marrow transplantation 2001;27(9):925-31.
2001: M C Legdeur; M G Broekhoven; Gerrit J Schuurhuis; Robert H J Beelen; Gert Ossenkoppele
Monocyte-chemoattractant-protein-1-mediated migration of human monocytes towards blasts from patients with acute myeloid leukemia.
Cancer immunology, immunotherapy : CII 2001;50(1):16-22.
2001: Gerrit J Schuurhuis; M M Muijen; Jan W Oberink; Fransien de Boer; Gert Ossenkoppele; Henk J Broxterman
Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants.
Bone marrow transplantation 2001;27(5):487-98.
2001: Rosita L ten Berge; Joost Oudejans; Danny F Dukers; Jos W R Meijer; Gert Ossenkoppele; Chris J L M Meijer
Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker.
Leukemia 2001;15(3):458-64.
2000: Y Xie; Johan P de Winter; Quinten Waisfisz; A W M Nieuwint; Rik J Scheper; Fré Arwert; Maureen Hoatlin; Gert Ossenkoppele; Gerrit J Schuurhuis; Hans Joenje
Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells.
British journal of haematology 2000;111(4):1057-64.
2000: Dorina M van der Kolk; Elisabeth G E de Vries; W J van Putten; Leo F Verdonck; Gert Ossenkoppele; Gregor Verhoef; Edo Vellenga
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3205-14.
2000: Rosita L ten Berge; Joost Oudejans; Gert Ossenkoppele; K Pulford; Rein Willemze; B Falini; Andreas Chott; Chris J L M Meijer
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
Journal of clinical pathology 2000;53(6):445-50.
2000: Henk J Broxterman; Pieter Sonneveld; W J van Putten; Jan Lankelma; CA Eekman; Gert Ossenkoppele; HERBERT PINEDO; Bob Löwenberg; Gerrit J Schuurhuis
P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.
Leukemia 2000;14(6):1018-24.
2000: J J W M Janssen; R S van Rijn; Bronno van der Holt; Gerrit J Schuurhuis; Edo Vellenga; Gregor Verhoef; Gert Ossenkoppele; Eva van den Berg; A Hagemeijer; R Släter; A W M Nieuwint; Jan J Cornelissen
Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.
Bone marrow transplantation 2000;25(11):1147-55.
2000: Dorina M van der Kolk; Edo Vellenga; Anneke Y van der Veen; L Noordhoek; Hetty Timmer-Bosscha; Gert Ossenkoppele; R A Raymakers; Michael Müller; Eva van den Berg; Elisabeth G E de Vries
Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity.
Blood 2000;95(11):3514-9.
1999: Carin A Uyl-de Groot; Gert Ossenkoppele; Ivonne Buijt; Peter C Huijgens
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
Journal of hematotherapy & stem cell research 1999;8(6):619-25.
1999: S Thijsen; Gerrit J Schuurhuis; Johan W van Oostveen; Gert Ossenkoppele
Chronic myeloid leukemia from basics to bedside.
Leukemia 1999;13(11):1646-74.
1999: Gert Ossenkoppele; Bronno van der Holt; Gregor Verhoef; S M G J Daenen; Leo F Verdonck; Pieter Sonneveld; Pierre W Wijermans; Johannes Van Der Lelie; Wim L J van Putten; Bob Löwenberg
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.
Leukemia 1999;13(8):1207-13.
1999: Peter C Huijgens; Alberdina M Simoons-Smit; Andre C D van Loenen; E Prooy; H van Tinteren; Gert Ossenkoppele; Andries R Jonkhoff
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Journal of clinical pathology 1999;52(5):376-80.
1999: Rosita L ten Berge; Danny F Dukers; Joost Oudejans; K Pulford; Gert Ossenkoppele; Daphne de Jong; J F Miseré; Chris J L M Meijer
Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma.
Blood 1999;93(8):2688-96.
1999: Carin A Uyl-de Groot; Gert Ossenkoppele; Ivonne Buijt; Peter C Huijgens
Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
PharmacoEconomics 1999;15(3):305-11.
1999: SF Thijsen; Gerrit J Schuurhuis; Johan W van Oostveen; AP Theijsmeijer; Klaas G van der Hem; J H Odding; Angelika M Dräger; Gert Ossenkoppele
Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.
British journal of cancer 1999;79(9-10):1406-12.
1999: Danny F Dukers; Rosita L ten Berge; Joost Oudejans; K Pulford; D Hayes; J F Miseré; Gert Ossenkoppele; Lies H Jaspars; Rein Willemze; Chris J L M Meijer
A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas.
Journal of clinical pathology 1999;52(2):129-36.
1999: Henk J Broxterman; Pieter Sonneveld; Rob Pieters; Jan Lankelma; CA Eekman; Anne H Loonen; M Schoester; Gert Ossenkoppele; Bob Löwenberg; HERBERT PINEDO; Gerrit J Schuurhuis
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
Leukemia 1999;13(2):258-65.
1998: Ivonne Buijt; Gert Ossenkoppele; Carin A Uyl-de Groot; Peter C Huijgens
Costs of intensive treatment and follow-up of patients with multiple myeloma.
Anti-cancer drugs 1998;9(10):889-97.
1998: Janetta Bijl; Johan W van Oostveen; Jan M M Walboomers; A T Brink; Wim Vos; Gert Ossenkoppele; Chris J L M Meijer
Differentiation and cell-type-restricted expression of HOXC4, HOXC5 and HOXC6 in myeloid leukemias and normal myeloid cells.
Leukemia 1998;12(11):1724-32.
1998: T Szczepański; Anton Langerak; Ingrid L M Wolvers-Tettero; Gert Ossenkoppele; G Verhoef; Michel Stul; E J Petersen; MA de Bruijn; Mars B van't Veer; Jacques J M van Dongen
Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease.
Leukemia 1998;12(7):1081-8.
1998: Antoinette A T P Brink; Joost Oudejans; Adriaan J C van den Brule; P M Kluin; A Horstman; Gert Ossenkoppele; P van Heerde; M Jiwa; Chris J L M Meijer
Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance?
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1998;11(4):376-83.
1998: Angelika M Dräger; Gert Ossenkoppele; Andries R Jonkhoff; Gerrit J Schuurhuis; Peter C Huijgens
New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 1998;31(1):49-53.
1997: Bob Löwenberg; Marc Boogaerts; S M G J Daenen; Gregor Verhoef; Anton Hagenbeek; Edo Vellenga; Gert Ossenkoppele; Peter C Huijgens; Leo F Verdonck; Johannes Van Der Lelie; JJ Wielenga; Harry C Schouten; Jürg Gmür; Alois Gratwohl; U Hess; M F Fey; Wim L J van Putten
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(12):3496-506.
1997: SF Thijsen; Gerrit J Schuurhuis; Johan W van Oostveen; AP Theijsmeijer; A W Niewint; Gert Ossenkoppele
Mobilization of hematopoietic progenitors in patients with chronic myeloid leukemia.
Bone marrow transplantation 1997;20(10):835-42.
1997: M C Legdeur; R H Beelen; Gerrit J Schuurhuis; M G Broekhoven; Arjan A van de Loosdrecht; Janneke Tekstra; MM Langenhuijsen; Gert Ossenkoppele
A functional study on the migration of human monocytes to human leukemic cell lines and the role of monocyte chemoattractant protein-1.
Leukemia 1997;11(11):1904-8.
1997: Bob Löwenberg; Stefan Suciu; Eric Archimbaud; Gert Ossenkoppele; Gregor Verhoef; E Vellenga; Pierre W Wijermans; Zwi Berneman; Adriaan W Dekker; Pierre Stryckmans; Harry Schouten; Ulrich Jehn; Petra Muus; Pieter Sonneveld; M Dardenne; Robert Zittoun
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
Blood 1997;90(8):2952-61.
1997: SF Thijsen; Johan W van Oostveen; Gerrit J Schuurhuis; AP Theijsmeijer; Cees B M Oudejans; Inge J van Wijk; MM Langenhuijsen; Gert Ossenkoppele
Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia.
Leukemia 1997;11(10):1762-8.
1997: Henk J Broxterman; Jan Lankelma; HERBERT PINEDO; CA Eekman; D C Währer; Gert Ossenkoppele; Gerrit J Schuurhuis
Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia.
Leukemia 1997;11(7):1110-8.
1997: Joost Oudejans; N Mehdi Jiwa; J Alain Kummer; Gert Ossenkoppele; P van Heerde; Joke W Baars; Philip M Kluin; Johanna C Kluin-Nelemans; Paulus van Diest; Jaap Middeldorp; Chris J L M Meijer
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease.
Blood 1997;89(4):1376-82.
1997: Adriaan W Dekker; Mars B van't Veer; W Sizoo; H L Haak; Johannes Van Der Lelie; Gert Ossenkoppele; Peter C Huijgens; Harry C Schouten; Pieter Sonneveld; Rein Willemze; Leo F Verdonck; Wim L J van Putten; Bob Löwenberg
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):476-82.
1997: SF Thijsen; Gerrit J Schuurhuis; Johan W van Oostveen; AP Theijsmeijer; MM Langenhuijsen; Gert Ossenkoppele
Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridization compared with RT-PCR.
Leukemia 1997;11(2):301-5.
1997: Bob Löwenberg; Wim L J van Putten; A Ferrant; Gert Ossenkoppele; Edo Vellenga; Leo F Verdonck; A Gratwohl; M A Boogaerts
Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia.
Stem cells (Dayton, Ohio) 1997;15 Suppl 1():177-80; discussion 181.
1996: Gert Ossenkoppele; Gerrit J Schuurhuis; Andries R Jonkhoff; Klaas G van der Hem; M C Legdeur; A Boot-Bakker; A H Westra; Angelika M Dräger; Peter C Huijgens
High-dose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma.
European journal of cancer (Oxford, England : 1990) 1996;32A(12):2058-63.
1996: M C Legdeur; P M Bontje; Gert Ossenkoppele; Robert H J Beelen; A A van de Loosdrecht; M G Broekhoven; MM Langenhuijsen; SF Thijsen; H Hofstee; Gerrit J Schuurhuis
The role of BCL-2 and bax protein in monocyte-mediated apoptosis in human leukemic cell lines.
Experimental hematology 1996;24(13):1530-9.
1996: Gert Ossenkoppele; Gerrit J Schuurhuis; Andries R Jonkhoff; Angelika M Dräger; G Westra; J W Oberink; M C Legdeur; A M de Kreuk; S Zweegman; Peter C Huijgens
G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma.
Bone marrow transplantation 1996;18(2):427-31.
1996: M de Kreuk; Gert Ossenkoppele; C J Meijer; Peter C Huijgens
Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation.
Bone marrow transplantation 1996;17(6):963-71.
1996: E Klumper; Gert Ossenkoppele; Rob Pieters; D R Huismans; A H Loonen; A Rottier; G Westra; Anjo J P Veerman
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
British journal of haematology 1996;93(4):903-10.
1996: Henk J Broxterman; Pieter Sonneveld; Nicole Feller; Gert Ossenkoppele; D C Währer; CA Eekman; M Schoester; Jan Lankelma; HERBERT PINEDO; Bob Löwenberg; Gerrit J Schuurhuis
Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
Blood 1996;87(11):4809-16.
1996: Joost Oudejans; J Alain Kummer; M Jiwa; Paul Van Der Valk; Gert Ossenkoppele; Philip M Kluin; J C Kluin-Nelemans; Chris J L M Meijer
Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease.
The American journal of pathology 1996;148(1):233-40.
1995: Andries R Jonkhoff; M A Plaizier; Gert Ossenkoppele; Gerrit J J Teule; Peter C Huijgens
High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a feasibility study.
British journal of cancer 1995;72(6):1541-6.
1995: Joost Oudejans; Adriaan J C van den Brule; N Mehdi Jiwa; P C de Bruin; Gert Ossenkoppele; Paul Van Der Valk; Jan M M Walboomers; Chris J L M Meijer
BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes.
Blood 1995;86(5):1893-902.
1995: J Van Gorp; P C De Bruin; D M Sie-Go; P Van Heerde; Gert Ossenkoppele; L H Rademakers; Chris J L M Meijer; Jan G van den Tweel
Nasal T-cell lymphoma: a clinicopathological and immunophenotypic analysis of 13 cases.
Histopathology 1995;27(2):139-48.
1995: Andries R Jonkhoff; Peter C Huijgens; R T Versteegh; A van Lingen; Gert Ossenkoppele; Angelika M Dräger; Gerrit J J Teule
Radiotoxicity of 67-gallium on myeloid leukemic blasts.
Leukemia research 1995;19(3):169-74.
1995: Gerrit J Schuurhuis; Henk J Broxterman; Gert Ossenkoppele; Jan P A Baak; CA Eekman; CM Kuiper; Nicole Feller; T H van Heijningen; E Klumper; Rob Pieters
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(1):81-93.
1994: P C de Bruin; J Alain Kummer; Paul Van Der Valk; P van Heerde; Philip M Kluin; Rein Willemze; Gert Ossenkoppele; T Radaszkiewicz; Chris J L M Meijer
Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization.
Blood 1994;84(11):3785-91.
1994: A A van de Loosdrecht; Robert H J Beelen; Gert Ossenkoppele; M G Broekhoven; MM Langenhuijsen
A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia.
Journal of immunological methods 1994;174(1-2):311-20.
1994: A A van de Loosdrecht; Gert Ossenkoppele; Robert H J Beelen; M G Broekhoven; M H A van Hooff; Angelika M Dräger; Peter C Huijgens; MM Langenhuijsen
Maturation-dependent susceptibility to monocyte-mediated cytotoxicity in acute myeloid leukemia.
Leukemia 1994;8(8):1392-400.
1994: A A van de Loosdrecht; Gert Ossenkoppele; Robert H J Beelen; M G Broekhoven; K M Schweitzer; MM Langenhuijsen
In vitro purging of clonogenic leukaemic cells from human bone marrow by interferon-gamma-activated monocytes.
Cancer immunology, immunotherapy : CII 1994;38(5):346-52.
1994: B Kiburg; A A van de Loosdrecht; K M Schweitzer; Gert Ossenkoppele; L J Müller; Jan J Heimans; Peter C Huijgens
Effects of the ACTH(4-9) analogue, ORG 2766, on vincristine cytotoxicity in two human lymphoma cell lines, U937 and U715.
British journal of cancer 1994;69(3):497-501.
1994: LA Noorduyn; P C de Bruin; P van Heerde; M M van de Sandt; Gert Ossenkoppele; Chris J L M Meijer
Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.
Journal of clinical pathology 1994;47(1):33-7.
1994: Gert Ossenkoppele; Andries R Jonkhoff; Peter C Huijgens; J J Nauta; Klaas G van der Hem; Angelika M Dräger; MM Langenhuijsen
Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
Bone marrow transplantation 1994;13(1):37-41.
1994: Carin A Uyl-de Groot; Gert Ossenkoppele; A A van Riet; Frans F H Rutten
The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma.
European journal of cancer (Oxford, England : 1990) 1994;30A(4):457-9.
1993: P C De Bruin; N Mehdi Jiwa; Paul Van Der Valk; P Van Heerde; R Gordijn; Gert Ossenkoppele; Jan M M Walboomers; Chris J L M Meijer
Detection of Epstein-Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas: relation between latent membrane protein-1 positivity and clinical course.
Histopathology 1993;23(6):509-18.
1993: Otto S Hoekstra; Arthur van Lingen; Gert Ossenkoppele; R Golding; Gerrit J J Teule
Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography.
European journal of nuclear medicine 1993;20(12):1214-7.
1993: A A van de Loosdrecht; Gert Ossenkoppele; Robert H J Beelen; M G Broekhoven; Angelika M Dräger; MM Langenhuijsen
Apoptosis in tumor necrosis factor-alpha-dependent, monocyte-mediated leukemic cell death: a functional, morphologic, and flow-cytometric analysis.
Experimental hematology 1993;21(13):1628-39.
1993: Otto S Hoekstra; Gert Ossenkoppele; R Golding; Arthur van Lingen; Gerard W M Visser; Gerrit J J Teule; Peter C Huijgens
Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1993;34(10):1706-10.
1993: Peter C Huijgens; Andries R Jonkhoff; Otto S Hoekstra; Gert Ossenkoppele; Gerrit J J Teule
Therapeutic potential of intravenous 67-gallium in non-Hodgkin's lymphoma.
European journal of haematology 1993;51(4):206-8.
1993: A A van de Loosdrecht; Gert Ossenkoppele; Robert H J Beelen; M G Broekhoven; MM Langenhuijsen
Cell cycle specific effects of tumor necrosis factor alpha in monocyte mediated leukemic cell death and the role of beta 2-integrins.
Cancer research 1993;53(18):4399-407.
1993: Mars B van't Veer; Wim L J van Putten; Leo F Verdonck; Gert Ossenkoppele; Bob Löwenberg; Johanna C Kluin-Nelemans; P W Wijermans; Harry C Schouten; W Sizoo; Adriaan W Dekker
Acute lymphoblastic leukaemia in adults: immunological subtypes and clinical features at presentation.
Annals of hematology 1993;66(6):277-82.
1993: P C de Bruin; A L Noorduyn; Paul Van Der Valk; P van Heerde; Paulus van Diest; M M van de Sandt; Gert Ossenkoppele; Chris J L M Meijer
Noncutaneous T-cell lymphomas. Recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis.
Cancer 1993;71(8):2604-12.
1993: Andries R Jonkhoff; Peter C Huijgens; R T Versteegh; E B van Dieren; Gert Ossenkoppele; H J Martens; Gerrit J J Teule
Gallium-67 radiotoxicity in human U937 lymphoma cells.
British journal of cancer 1993;67(4):693-700.
1993: C M Schweitzer; A A van de Loosdrecht; Andries R Jonkhoff; Gert Ossenkoppele; Peter C Huijgens; Angelika M Dräger; M G Broekhoven; MM Langenhuijsen
Spectrophotometric determination of clonogenic capacity of leukemic cells in a semisolid microtiter culture system.
Experimental hematology 1993;21(4):573-8.
1993: I A Denkers; T J de Jong-de Boer; R H Beelen; Gert Ossenkoppele; J J Nauta; MM Langenhuijsen
Adhesive capacity of human long-term bone marrow cultures from normals and patients with acute myeloid leukaemia: the influence of adhesion molecules.
Leukemia research 1993;17(3):255-61.
1993: A A van de Loosdrecht; Robert H J Beelen; Gert Ossenkoppele; M G Broekhoven; MM Langenhuijsen
Cellular and cytokine dependent monocyte-mediated leukemic cell death: modulation by interferon-gamma and tumor necrosis factor-alpha.
Experimental hematology 1993;21(3):461-8.
1993: Peter C Huijgens; Andre C D van Loenen; A M Simoons-Smit; E Prooy; Gert Ossenkoppele
The prophylactic use of fluconazole 50 vs. 100 mg daily in haematological malignancies.
European journal of cancer (Oxford, England : 1990) 1993;29A(6):926-7.
1993: Tjeerd J Postma; B A Benard; Peter C Huijgens; Gert Ossenkoppele; Jan J Heimans
Long-term effects of vincristine on the peripheral nervous system.
Journal of neuro-oncology 1993;15(1):23-7.
1992: B van Kooten; H A van Diemen; K M Groenhout; Peter C Huijgens; Gert Ossenkoppele; J J Nauta; Jan J Heimans
A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy.
Archives of neurology 1992;49(10):1027-31.
1992: Klaas G van der Hem; Gert Ossenkoppele
All-trans retinoic acid toxicity.
European journal of haematology 1992;49(3):148-9.
1992: E C van Pampus; I A Denkers; B J van Geel; Peter C Huijgens; A Zevenbergen; Gert Ossenkoppele; MM Langenhuijsen
Expression of adhesion antigens of human bone marrow megakaryocytes, circulating megakaryocytes and blood platelets.
European journal of haematology 1992;49(3):122-7.
1992: I A Denkers; R H Beelen; Gert Ossenkoppele; A J de Jong-de Boer; MM Langenhuijsen
Differences of cellular composition and adhesion molecule expression in "leukemic" as compared with "normal" human long-term bone marrow cultures.
Annals of hematology 1992;64(5):210-6.
1992: I A Denkers; T J de Jong-de Boer; R H Beelen; Gert Ossenkoppele; MM Langenhuijsen
VLA molecule expression may be involved in the release of acute myeloid leukaemic cells from the bone marrow.
Leukemia research 1992;16(5):469-74.
1992: Vivienne Rebel; Gert Ossenkoppele; A A van de Loosdrecht; P W Wijermans; R H Beelen; MM Langenhuijsen
Monocytic differentiation induction of HL-60 cells by MC 903, a novel vitamin D analogue.
Leukemia research 1992;16(5):443-51.
1992: A A van de Loosdrecht; Gert Ossenkoppele; Robert H J Beelen; M G Broekhoven; MM Langenhuijsen
Role of interferon gamma and tumour necrosis factor alpha in monocyte-mediated cytostasis and cytotoxicity against a human histiocytic lymphoma cell line.
Cancer immunology, immunotherapy : CII 1992;34(6):393-8.
1992: Arthur van Lingen; Peter C Huijgens; Frans C Visser; Gert Ossenkoppele; Otto S Hoekstra; H J Martens; H Huitink; K D Herscheid; M V Green; Gerrit J J Teule
Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera.
European journal of nuclear medicine 1992;19(5):315-21.
1991: E C van Pampus; B J van Geel; Peter C Huijgens; P W Wijermans; Gert Ossenkoppele; F Rodriguez; A Zevenbergen; MM Langenhuijsen
Combining counterflow centrifugal elutriation and glycoprotein Ib-dependent purification of human megakaryocytes: efficacy and selectivity.
European journal of haematology 1991;47(4):299-304.
1991: A A van de Loosdrecht; E Nennie; Gert Ossenkoppele; Robert H J Beelen; MM Langenhuijsen
Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study.
Journal of immunological methods 1991;141(1):15-22.
1991: Peter C Huijgens; Gert Ossenkoppele; J Van Der Lelie; L L Thomas; M J Wijngaarden; C M Slaper
IMVP-16 followed by high dose chemotherapy and autologous bone marrow transplantation as salvage treatment for malignant lymphoma.
Hematological oncology 1991;9(4-5):245-51.
1991: Peter C Huijgens; Gert Ossenkoppele; T F Weijers; Andre C D van Loenen; A M Simoons-Smit; P W Wijermans; E C van Pampus; MM Langenhuijsen
Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies.
European journal of haematology 1991;46(1):42-6.
1991: LA Noorduyn; R Torenbeek; Paul Van Der Valk; P B Drosten; Gordon B Snow; A J Balm; Gert Ossenkoppele; C J Meyer
Sinonasal non-Hodgkin's lymphomas and Wegener's granulomatosis: a clinicopathological study.
Virchows Archiv. A, Pathological anatomy and histopathology 1991;418(3):235-40.
1991: Gert Ossenkoppele; P W Wijermans; J J Nauta; Peter C Huijgens; MM Langenhuijsen
Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: in vivo and in vitro cytotoxicity.
European journal of cancer (Oxford, England : 1990) 1991;27(7):842-5.
1991: Gert Ossenkoppele; P J Wijermans; Peter C Huijgens; J J Nauta; MM Langenhuijsen
Quantitative enzyme determination in acute myeloid leukemia.
Leukemia research 1991;15(6):481-6.
1990: Jan J Heimans; P W Wijermans; C H Polman; Peter C Huijgens; Gert Ossenkoppele; G J van Kamp
Longterm meningeal involvement as the only clinical manifestation of low grade malignant non-Hodgkin's lymphoma.
Journal of neuro-oncology 1990;9(3):275-7.
1990: M C Blonk; P van der Valk; G C Beverstock; Gert Ossenkoppele
Sequential development of peripheral T-cell lymphoma in the course of chronic myelogenous leukemia.
Cancer 1990;66(6):1198-203.
1990: Gert Ossenkoppele; I Denkers; P Wijermans; Peter C Huijgens; J J Nauta; R J Beelen; M M Langenhuijsen
Differentiation induction of HL60 cells in a long-term bone marrow culture of acute myeloid leukemia.
Leukemia research 1990;14(7):611-6.
1990: E C van Pampus; Peter C Huijgens; P W Wijermans; Gert Ossenkoppele; MM Langenhuijsen
Purification of human megakaryocytes using a glycoprotein Ib dependent agglutination technique.
Clinical and laboratory haematology 1990;12(3):301-7.
1989: Gert Ossenkoppele; P W Wijermans; F C de Waal; T A vd Berg; W Jalink; Peter C Huijgens; MM Langenhuijsen
Low dose cytosine-arabinoside has only minimal differentiation inducing capacity in HL60 cells.
European journal of cancer & clinical oncology 1989;25(11):1561-9.
1989: P W Wijermans; Vivienne Rebel; Gert Ossenkoppele; Peter C Huijgens; MM Langenhuijsen
Combined procoagulant activity and proteolytic activity of acute promyelocytic leukemic cells: reversal of the bleeding disorder by cell differentiation.
Blood 1989;73(3):800-5.
1989: Gert Ossenkoppele; P W Wijermans; J J Nauta; Peter C Huijgens; MM Langenhuijsen
Maturation induction in freshly isolated human myeloid leukemic cells, 1.25 (OH)2 vitamin D3 being the most potent inducer.
Leukemia research 1989;13(7):609-14.
1988: Peter C Huijgens; Gert Ossenkoppele; J van der Lelie; L L Thomas; M J Wijngaarden; R M Reijneke
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
European journal of cancer & clinical oncology 1988;24(3):483-6.
1987: Peter C Huijgens; Gert Ossenkoppele; M van der Weide; M J Wijngaarden; R M Reijneke; P W Wijermans; M M Langenhuijsen
High-dose busulfan and amsacrine with autologous bone marrow rescue in patients with acute myeloid leukemia in first remission.
Cancer treatment reports 1987;71(5):552-3.